Axon Enterprise, Inc. (A2XO34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 124.80 |
|---|---|
| 52-week range | 94.60 – 227.46 |
| Return, 1 month / 3 months | +0.5% / −15.5% |
| Return, 1 year / 3 years | −44.0% / +110.4% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 66.6% |
| Worst drawdown (1 year) | -57.2% |
| Average daily value traded | 0.06M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Axon Enterprise makes conducted energy weapons, body cameras and cloud software for police and public safety agencies. Its devices and digital evidence tools help law enforcement officers record incidents and manage footage. The company also provides training and support services tied to those products. Axon Enterprise is based in Scottsdale, Arizona, in the United States, and serves police departments, government agencies and other customers around the world.
Axon Enterprise, Inc. is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A2XO34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Axon Enterprise, Inc. (A2XO34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 124.80 on 27 October 2026.
Its price-based Market X-Ray is 27 out of 100 (a weak price profile), ranking 1,250 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 44.0% and over the last three months it fell 15.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 25 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.0% | ||
| From 52-week high | -44.6% | ||
| Momentum | 26 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -15.5% | ||
| 6-month return | 11.7% | ||
| 12-month return, skipping the last month | -44.3% | ||
| Stability (higher is calmer) | 14 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 66.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -57.2% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.06M BRL | ||
| Zero-volume days | 13.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +17.0% |
|---|---|
| 1 month | +0.5% |
| 3 months | −15.5% |
| 6 months | +11.7% |
| 1 year | −44.0% |
| 3 years | +110.4% |
| 5 years | – |
Signals
| 50-day / 200-day average | 137.33 / 138.65 |
|---|---|
| Golden / death cross (60 days) | Death, 2 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.25 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.